Advanced search×

Expert Opinion on Investigational Drugs

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
CSA, Proquest, Ingenta, Informaworld, Rcgp, and Informahealthcare

  1. Antibacterial drug discovery & development summit.

    Expert Opinion on Investigational Drugs 13(6):715 (2004) PMID 15174958

    Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. I...
  2. Vascular biology support for the use of bevacizumab in colorectal cancer.

    Expert Opinion on Investigational Drugs 13(6):703 (2004) PMID 15174956

    In colorectal cancer, increased expression of the angiogenesis promoter vascular endothelial growth factor correlates with invasiveness, vascular density, metastases, recurrence and prognosis. Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor. In re...
  3. Novel targeted agents in the treatment of lung cancer.

    Expert Opinion on Investigational Drugs 13(6):609 (2004) PMID 15174948

    Lung cancer is the leading cause of cancer-related mortality in the US. Although an improvement in outcome is possible with the continued advancement of cytotoxic-based treatment, clinical research is currently focused on utilising novel molecular targets with proven efficacy in preclinical mode...
  4. Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.

    Expert Opinion on Investigational Drugs 13(6):707 (2004) PMID 15174957

    Current international guidelines recommend that the goal of treatment with lipid-lowering therapy in patients with established coronary artery disease (CAD) should be a low-density lipoprotein cholesterol level of < 100 mg/dl. The question that remains to be answered is whether more aggressive l...
  5. Colon cancer angiogenesis and antiangiogenic therapy.

    Expert Opinion on Investigational Drugs 13(6):631 (2004) PMID 15174949

    Metastatic development is the primary cause of cancer treatment failure and is responsible for most deaths from colorectal cancer. For the majority of patients, by the time primary colorectal cancers are diagnosed, sub-clinical or clinically relevant liver metastases have already occurred. The f...
  6. Cataract formation and prevention.

    Expert Opinion on Investigational Drugs 13(6):691 (2004) PMID 15174955

    Cataract, a leading cause of blindness worldwide, is a multifactorial eye disease. In developing countries the incidence of cataract among young generations is not uncommon due to malnutrition, excess exposure to ultraviolet radiation and so on. In developed countries, age-related cataract affec...
  7. Immunotherapeutics for nosocomial infections.

    Expert Opinion on Investigational Drugs 13(6):673 (2004) PMID 15174953

    Nosocomial or hospital-acquired infections are associated with prolonged hospitalisation and increased healthcare costs and resource utilisation. Continued advances in sophisticated medical procedures, an increase in the number of immunocompromised patients and a steady rise in the prevalence of...
  8. The potential of Na+/Ca2+ exchange blockers in the treatment of cardiac disease.

    Expert Opinion on Investigational Drugs 13(6):653 (2004) PMID 15174951

    The Na(+)/Ca(2+) exchanger (NCX), a surface membrane antiporter, is the primary pathway for Ca(2+) efflux from the cardiac cell and a determinant of both the electrical and contractile state of the heart. Enhanced expression of NCX has recently been recognised as one of the molecular mechanisms ...
  9. Molecular biological design of novel antineoplastic therapies.

    Expert Opinion on Investigational Drugs 13(6):577 (2004) PMID 15174947

    Novel therapies represent a new strategy for the development of anticancer agents. New targets derived from the knowledge of the molecular structure and genetic defects has been useful in developing anticancer drugs that prolong or stabilise the progression of tumours with minimal systemic toxic...
  10. Vaccines for the prevention of respiratory viral infections: problems and current status.

    Expert Opinion on Investigational Drugs 13(6):681 (2004) PMID 15174954

    Acute respiratory virus infections cause the majority of lower respiratory tract illnesses and hospitalisations of infants and the elderly. The emergence of new respiratory viruses and a high probability that influenza will cause further pandemics highlights the necessity for developing better p...